I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 11 studies | 27% ± 13% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 11 studies | 27% ± 13% |
Insufficient scRNA-seq data for expression of CHADL at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 1505.37 | 2639 / 2642 | 99% | 48.37 | 696 / 705 |
| prostate | 100% | 475.78 | 244 / 245 | 99% | 12.66 | 496 / 502 |
| thymus | 93% | 301.01 | 608 / 653 | 98% | 9.08 | 591 / 605 |
| esophagus | 97% | 447.85 | 1399 / 1445 | 58% | 2.58 | 107 / 183 |
| bladder | 76% | 198.10 | 16 / 21 | 71% | 4.34 | 360 / 504 |
| ovary | 78% | 148.65 | 141 / 180 | 63% | 2.65 | 271 / 430 |
| breast | 64% | 175.27 | 294 / 459 | 70% | 4.45 | 786 / 1118 |
| skin | 70% | 273.15 | 1271 / 1809 | 61% | 12.35 | 286 / 472 |
| stomach | 87% | 307.69 | 314 / 359 | 40% | 1.57 | 115 / 286 |
| uterus | 47% | 89.78 | 80 / 170 | 77% | 4.63 | 353 / 459 |
| intestine | 81% | 640.26 | 784 / 966 | 39% | 1.61 | 208 / 527 |
| adrenal gland | 61% | 165.40 | 157 / 258 | 53% | 3.37 | 122 / 230 |
| pancreas | 35% | 56.24 | 114 / 328 | 71% | 3.27 | 127 / 178 |
| lung | 37% | 67.90 | 216 / 578 | 64% | 3.17 | 740 / 1155 |
| ureter | 0% | 0 | 0 / 0 | 100% | 4.35 | 1 / 1 |
| heart | 95% | 635.60 | 820 / 861 | 0% | 0 | 0 / 0 |
| liver | 31% | 58.26 | 70 / 226 | 61% | 4.61 | 246 / 406 |
| eye | 0% | 0 | 0 / 0 | 91% | 18.08 | 73 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 89% | 5.71 | 40 / 45 |
| kidney | 40% | 76.20 | 36 / 89 | 39% | 1.42 | 352 / 901 |
| adipose | 44% | 86.06 | 533 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 30% | 59.29 | 403 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 11% | 17.30 | 87 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 0.27 | 3 / 29 |
| spleen | 4% | 5.29 | 9 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_1904027 | Biological process | negative regulation of collagen fibril organization |
| GO_0032331 | Biological process | negative regulation of chondrocyte differentiation |
| GO_0005615 | Cellular component | extracellular space |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0031012 | Cellular component | extracellular matrix |
| GO_0030021 | Molecular function | extracellular matrix structural constituent conferring compression resistance |
| GO_0005518 | Molecular function | collagen binding |
| GO_0098633 | Molecular function | collagen fibril binding |
| Gene name | CHADL |
| Protein name | Chondroadherin like Chondroadherin-like protein |
| Synonyms | SLRR4B |
| Description | FUNCTION: Potential negative modulator of chondrocyte differentiation. Inhibits collagen fibrillogenesis in vitro. May influence chondrocyte's differentiation by acting on its cellular collagenous microenvironment. . |
| Accessions | H0Y4I5 ENST00000455425.1 ENST00000417999.5 ENST00000216241.14 [Q6NUI6-1] B0QYT2 Q6NUI6 |
